• Aiuto
  • Sfoglia

    • DI NICOLANTONIO, Federica

    Rete di Collaborazioni Statistiche Email Alert RSS Feed

    Pubblicazioni (Tutti)

    Risultati 1 - 20 di 122 (tempo di esecuzione: 0.001 secondi).

    TitoloData di pubblicazioneAutore(i)
    1Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer2008Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    2Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers2015Misale, Sandra; Bozic, Ivana; Tong, Jingshan; Peraza-Penton, Ashley; Lallo, Alice; Baldi, Federica; Lin, Kevin H.; Truini, Mauro; Trusolino, Livio; Bertotti, Andrea; Di Nicolantonio, Federica; Nowak, Martin A.; Zhang, Lin; Wood, Kris C.; Bardelli, Alberto
    3VEGF blockade enhances the antitumor effect of BRAFV600E inhibition2017Comunanza, Valentina; Cora', Davide; Orso, Francesca; Consonni, Francesca Maria; Middonti, Emanuele; DI NICOLANTONIO, Federica; Buzdin, Anton; Sica, Antonio; Medico, Enzo; Sangiolo, Dario; Taverna, Daniela; Bussolino, Federico
    4Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer2002Di Nicolantonio F; Neale MH; Knight LA; Lamont A; Skailes GE; Osborne RJ; Allerton R; Kurbacher CM; Cree IA
    5Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening2013V. Boscaro; D. Zecchin; A. Bardelli; F. Di Nicolantonio; M. Gallicchio
    6Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR2012Prahallad A*; Sun C*; Huang S*; Di Nicolantonio F*; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R (*shared first authorship)
    7Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer2016Amatu, A; Barault, L; Moutinho, C; Cassingena, A; Bencardino, K; Ghezzi, S; Palmeri, L; Bonazzina, E; Tosi, F; Ricotta, R; Cipani, T; Crivori, P; Gatto, R; Chirico, G; Marrapese, G; Truini, M; Bardelli, A; Esteller, M; Di Nicolantonio, F; Sartore-Bianchi, A; Siena, S
    8Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer2016Russo, Mariangela; Siravegna, Giulia; Blaszkowsky, Lawrence S.; Corti, Giorgio; Crisafulli, Giovanni; Ahronian, Leanne G.; Mussolin, Benedetta; Kwak, Eunice L.; Buscarino, Michela; Lazzari, Luca; Valtorta, Emanuele; Truini, Mauro; Jessop, Nicholas A.; Robinson, Hayley E.; Hong, Theodore S.; Mino-Kenudson, Mari; Di Nicolantonio, Federica; Thabet, Ashraf; Sartore-Bianchi, Andrea; Siena, Salvatore; Iafrate, John; Bardelli, Alberto; ^*; Corcoran, Ryan B.; ^*; ^ joint co-last authorship; *joint corresponding authorship
    9Transfection and DNA-Mediated Gene Transfer2011Davide Zecchin; Federica Di Nicolantonio
    10Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor2017Siravegna, G; Sartore-Bianchi, A; Mussolin, B; Cassingena, A; Amatu, A; Novara, L; Buscarino, M; Corti, G; Crisafulli, G; Bartolini, A; Tosi, F; Erlander, M; Di Nicolantonio, F; Siena, S; Bardelli, A
    11Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers2011Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
    12Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer2010Sartore-Bianchi A; Bencardino K; Cassingena A; Venturini F; Funaioli C; Cipani T; Amatu A; Pietrogiovanna L; Schiavo R; Di Nicolantonio F; Artale S; Bardelli A; Siena S
    13The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours2004Knight LA; Di Nicolantonio F; Whitehouse P; Mercer S; Sharma S; Glaysher S; Johnson P; Cree IA
    14The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples2004Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Sharma S; Charlton PA; Norris D; Cree IA
    15The effect of imatinib mesylate (Glivec) on human tumor-derived cells2006Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    16TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.2014Hobor S;Van Emburgh BO;Crowley E;Misale S;Di Nicolantonio F;Bardelli A
    17Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation2018Morano, F.; Corallo, S.; Niger, M.; Barault, L.; Milione, M.; Berenato, R.; Moretto, R.; Randon, G.; Antista, M.; Belfiore, A.; Raimondi, A.; Nichetti, F.; Martinetti, A.; Battaglia, L.; Perrone, F.; Pruneri, G.; Falcone, A.; Di Bartolomeo, M.; De Braud, F.; Di Nicolantonio, F.; Cremolini, C.; Pietrantonio, F.
    18Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia2012Bottos A; Martini M; Di Nicolantonio F; Comunanza V; Maione F; Minassi A; Appendino G; Bussolino F; Bardelli A.
    19Targeted therapies: Tivantinib-a cytotoxic drug in MET inhibitor's clothes?2013Michieli P; Di Nicolantonio F
    20Targeted Knock-in of the Polymorphism rs61764370 Does Not Affect KRAS Expression but Reduces let-7 Levels2014Emily Hannah Crowley;Sabrina Arena;Simona Lamba;Federica Di Nicolantonio;Alberto Bardelli

    Dettaglio

    Nome completo:
    DI NICOLANTONIO, Federica
    struttura:
    ONCOLOGIA
    settore SSD:
    Settore BIO/10 - Biochimica
    Varianti:
    F. Di Nicolantonio
    FEDERICA DI NICOLANTONIO
    Di Nicolantonio F ^
    Di Nicolantonio F
    Di Nicolantonio F*
    Di Nicolantonio F #
    Di Nicolantonio F *
    Di Nicolantonio F#
    Di Nicolantonio F^
    Di Nicolantonio Federica
    di Nicolantonio F
    Di Nicolantonio Federica***
    Di Nicolantonio F***
    Di Nicolantonio, Federica*
    Di Nicolantonio, Federica***
    Di Nicolantonio, Federica
    Di Nicolantonio, F
    Di Nicolantonio, Federica**
     
     
     
    Powered by IRIS-about IRIS-Utilizzo dei cookie
    Logo CINECA  Copyright © 2020